MedTrace Logo

Dendritic Cells in Lung Cancer

NCT00442754 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2012-03-20

No results posted yet for this study

Summary

Vaccination with autologous dendritic cells pulsed with allogeneic melanoma cell lysate (MelCancerVac) in combination with the Cox-2 inhibitor of celecoxib for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). Adjuvant Aldara cream will be used as adjuvant for induction of inflammation at the injection site, and the lymphocyte growth factor of interleukin-2 (IL-2) will be given as s.c. injection. The treatment aims at boosting the patient's specific immune system against the cancer cells.

Conditions

  • Non Small Cell Lung Cancer

Interventions

BIOLOGICAL

Allogeneic Tumour Lysate (MelCancerVac)

subcutaneaus, /once weekly /4 wks then /4 weekly

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • Herlev Hospital

    lead OTHER

Principal Investigators

  • anders mellemgaard, MD PhD · Dept of Oncology, herlev university hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00442754 on ClinicalTrials.gov